Litcius/Paper detail

ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Carmen García-Durán, Juan Francisco Grau-Béjar, Guillermo Villacampa, Ana Oaknin

2022International Journal of Gynecological Cancer25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCervical cancerOncologyOpen labelRandomized controlled trialInternal medicineCancerEndometrial and Cervical Cancer TreatmentsCervical Cancer and HPV ResearchHER2/EGFR in Cancer Research
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation | Litcius